Avraham Pharmaceuticals
Prevention of Neurodegenerative Disorders
Company Name | Updating Date | Neurotech Category | Market Category | Target Market | Technologies | Company Founded Year | Company Number of Employees |
|---|---|---|---|---|---|---|---|
Avraham Pharmaceuticals | NeuroPharmacology | NeuroBioTechnology | Biotechnology & Biopharmaceutical | 01/01/2010 | "11-50" |
Avraham Pharmaceuticals is an emerging pharmaceutical company developing novel products for the treatment and prevention of neurodegenerative disorders such as Alzheimer's disease, Lewy body disease, and Parkinson's disease.
The company's lead product candidate, Ladostigil, was exclusively in-licensed from the Hebrew University and the Technion and is in phase 2 clinical studies for mild cognitive impairment (MCI). Ladostigil is a multifunctional compound that combines neuro-protective mechanisms, reducing oxidative stress and microglial activation while inhibiting pro-inflammatory cytokines. Ladostigil may have the potential to slow the progression of Alzheimer's disease in patients diagnosed with MCI.